The abstract is read at the publisher; the summary is JClub's.
In the REMATCH single-institution phase II trial of locally advanced head and neck cancer, 2-year disease-free survival reached 90% with universal laryngeal preservation.
- Why it matters: Organ preservation is a key goal for patients responding to neoadjuvant immunochemotherapy, but reducing local treatment without losing disease control remains challenging.
- What they did: The study tested reduced-volume surgery after neoadjuvant immunochemotherapy in patients with locally advanced head and neck cancer, using a phase II design to assess outcomes.
- The result: The 90% 2-year disease-free survival and universal laryngeal preservation support organ preservation by scaling back local therapy intensity and extent rather than switching to different modalities.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.